our product

Lifestyle changes resulting in cardiovascular diseases worldwide has increased the number of vascular grafting procedures. Due to lack of autologous graftable options in these patients, tissue engineered blood vessels that are readily available are in demand. The major problem of grafted vessels is occlusion, which can occur in absence of a healthy endothelium, especially in small diameter blood vessels. Current technologies utilize cell-based approaches, which are accompanied with long culture times and bioreactors, making them less feasible for "off-the-shelf" availability. There is a need for customizable vascular grafts, which can be manufactured on demand to enhance patient safety and outcomes while decreasing health care cost. Angiograft makes artificial blood vessels for treatment of cardiovascular disease. They are composed of collagenous biomaterials, which are functionalized sequentially with anti-clotting and self-cellularizing proteins. These enable them to attract the patients' own cells once implanted, making them biologically functional. At the end of the healing process, the fortified biomaterial is remodeled leaving behind a functional vascular graft made of the patients' own tissue.